Arcus Biosciences, Inc. (RCUS) Market Cap & Valuation Ratios
Arcus Biosciences, Inc. (RCUS) has a market cap of $2.4B and a price-to-sales ratio of 20.2, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
RCUSArcus Biosciences, Inc.Follow RCUS — free
—
Price chart with a free account
- Market cap
- 2.4B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 10 Nov, in 17 days
Peers
biotechnology · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| RCUS | 2.4 | — | 15.0 | — | — | -55% | -415% | -120% |
| VRDN | 2.5 | — | 26.8 | — | -13.2% | — | — | -48% |
| BEAM | 2.5 | — | 9.2 | — | — | +159% | -242% | -43% |
| ADMA | 2.4 | 15.3 | 4.8 | 10.6 | 4.9% | +8% | 44% | 37% |
| MBX | 2.3 | — | — | — | -3.6% | — | — | -44% |
| SLS | 2.3 | — | — | — | — | — | — | — |
| CLDX | 2.3 | — | — | — | -10.5% | -97% | — | -50% |
| FTRE | 2.2 | — | 1.2 | 46.4 | 8.7% | -2% | -0.4% | -0.7% |
| AUPH | 2.2 | — | 5.8 | 10.6 | 7.8% | +20% | 48% | 33% |
| PGEN | 2.2 | — | 26.5 | — | -5.2% | +147% | -46% | -33% |
| AGIO | 2.2 | — | 16.0 | — | — | +141% | -467% | -41% |
| Median of these 10 | 15.3 | 9.2 | 10.6 | -3.6% | +20% | -23% | -41% |
; EV/Sales 15.0 vs. 9.2.
Growth vs. price
each dot a company · hover or tap for valuesArcus Biosciences, Inc. — questions
- What is Arcus Biosciences, Inc.'s market cap?
- $2.4B.
- What is Arcus Biosciences, Inc.'s price-to-sales ratio?
- 20.2.
Every figure on this page comes from Arcus Biosciences, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.